Latin America Growth Leverage Alfasigma USA's expansion of offices into Mexico and the broader Americas, plus a focus on growing the Mexico OTC business, to position as a regional distributor for prescription nutritional products across GI, neuropsychiatric, diabetes-related, and cognitive health indications.

Portfolio Cross Sell With a portfolio including VSL#3 for GI disorders, Deplin for major depressive disorder, Metanx for diabetic peripheral neuropathy, and CerefolinNAC for mild cognitive impairment, there are multiple cross-selling opportunities across gastroenterology, psychiatry, endocrinology, and geriatrics.

US Growth Platform The new Bedminster commercial hub combined with strategic acquisitions such as Intercept Pharmaceuticals strengthens the US footprint and pipeline, creating sales opportunities with specialty physicians and hospital networks for niche therapies.

Leadership BD Push The appointment of senior commercial leadership from Galapagos signals a thrust to expand market access, partnerships, and co-promotion opportunities with major accounts and integrated care networks.

Data Driven Selling A tech stack featuring BI and ERP tools suggests potential to implement data driven account targeting, territory planning, and efficient order management to accelerate adoption of prescription nutrition therapies in targeted clinics and physician groups.